Urology Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

A model of prostate-specific antigen screening outcomes for low- to high-risk men
Archives of Internal Medicine, 09/30/09

Howard K et al. – Men should be informed of the likely benefits and harms of PSA screening. These estimates can be used to support individual decision making.

Methods

A Markov model compared patients with vs without annual PSA screening using a 20% relative risk (RR) reduction (RR = 0.8) in prostate cancer mortality as a best-case scenario; the model estimated numbers of biopsies, prostate cancers, and deaths from prostate cancer per 1000 men over 10 years and cumulated to age 85 years

Results

Using 60-year-old men with low risk as an example, of 1000 men screened annually, we estimate that 115 men will undergo biopsy triggered by an abnormal PSA screen result and that 53 men will be diagnosed as having prostate cancer over 10 years compared with 23 men diagnosed as having prostate cancer among 1000 unscreened men
Among screened men, 3.5 will die of prostate cancer over 10 years compared with 4.4 deaths in unscreened men
For 1000 men screened from 40 to 69 years of age, there will be 27.9 prostate cancer deaths and 639.5 deaths overall by age 85 years compared with 29.9 prostate cancer deaths and 640.4 deaths overall in unscreened men
Higher-risk men have more prostate cancer deaths averted but also more prostate cancers diagnosed and related harms

<< Previous
Translocator Protein Blockade Reduces Prostate Tumor Growth

Next >>
Dynamic Contrast-enhanced-magnetic Resonance Imaging Evaluation...